Kalbe Farma Tbk PT

Common Name
Kalbe Farma
Country
Indonesia
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
12,903
Ticker
KLBF
Exchange
INDONESIA STOCK EXCHANGE
Description
Kalbe Farma Tbk. PT is a prominent pharmaceutical corporation in Indonesia known for its extensive range of healthcare products and services. As a leader in the pharmaceutical industry, its primary fu...

Kalbe Farma's Financial Statements Preview

Below are the financial statements of Kalbe Farma, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Interested in getting early access to our real-time standardized financial datafeed?
Learn More
All figures in trillions of IDR
2024
2023
Net sales
32.63a
30.45a
Cost of goods sold
-19.67a
-18.63a
Gross profit
12.96a
11.82a
Selling expenses
-6.81a
-6.3a
General and administrative expenses
-1.51a
-1.5a
Research and development expenses
-0.47a
-0.33a
Other operating income
0.05a
0.06a
Other operating expenses
-0.13a
-0.16a
Interest income
0.18a
0.09a
Interest expense and financial charges
-0.07a
-0.1a
Share in gain of the associates, net
0.03a
0.03a
Income before income tax expense
4.22a
3.61a
Income tax expense
-0.97a
-0.83a
Income for the year
3.25a
2.78a
Download Data

Verified Sources Behind Kalbe Farma’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Kalbe Farma’s data sources below and access millions more through our Disclosure Search.

a. Kalbe Farma's Annual Report 2024
a. Kalbe Farma's Annual Report 2024
Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

Tracenable is building real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?